Willowdale, Canada

Mary E Ewasyshyn


Average Co-Inventor Count = 3.4

ph-index = 7

Forward Citations = 138(Granted Patents)


Location History:

  • Willowdale, CA (1998 - 2007)
  • Thornhill, CA (2000 - 2010)

Company Filing History:


Years Active: 1998-2010

Loading Chart...
27 patents (USPTO):Explore Patents

Title: **The Innovative Work of Mary E. Ewasyshyn in Immunogen Research**

Introduction

Mary E. Ewasyshyn is a distinguished inventor located in Willowdale, CA, known for his significant contributions to medical research and immunogen technology. With an impressive portfolio of 27 patents, Ewasyshyn has been instrumental in advancing the field of immunology, particularly in developing hybrid genes that can combat viral infections.

Latest Patents

Among his latest achievements are patents related to chimeric immunogens. These multimeric hybrid genes encode chimeric proteins that combine gene sequences from two different pathogens: the parainfluenza virus (PIV) and respiratory syncytial virus (RSV). His innovative work allows for the creation of a single recombinant immunogen capable of providing protection against diseases caused by both PIV and RSV in infants and vulnerable populations.

Career Highlights

Mary E. Ewasyshyn has taken his expertise to major companies, including Connaught Laboratories Limited and Sanofi Pasteur Inc. His work in these renowned organizations has positioned him as a leading figure in the development of vaccines and immunogens that are critical to public health.

Collaborations

Throughout his career, Ewasyshyn has collaborated with several notable professionals in the field. Among his esteemed coworkers are Michel Henri Klein and Run-Pan Du, whose combined expertise has paved the way for groundbreaking advancements in immunogen research.

Conclusion

Mary E. Ewasyshyn's commitment to innovation in immunogen technology positions him as a key contributor to the fight against infectious diseases. Through his patents and collaborations, he continues to support the development of effective vaccines that safeguard the health of vulnerable populations.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…